Cellular Biomedicine Group Executives to Present at Biotech and Money World HealthEx Forum in London
October 31 2017 - 8:00AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of effective immunotherapies for cancer and stem cell
therapies for degenerative diseases, today announced that CEO Tony
(Bizuo) Liu and SVP Andy Chan will present at the Biotech and Money
World HealthEx Forum and Inv€$tival Showcase in London held during
November 13 & 14, 2017.
Date: |
Monday, November 13,
2017 |
Time: |
11:40
|
Presenter: |
Tony (Bizuo) Liu,
CEO |
Title: |
Addressing Scale In
Personalized Advanced Therapies Manufacturing and Drug
Development |
Location: |
St Paul's, 200
Aldersgate, London, EC1A 4HD |
|
|
Date: |
Tuesday, November 14,
2017 |
Time: |
15:45 |
Presenter: |
Andy Chan, SVP |
Title: |
Investor Presentation
of CBMG |
Location: |
Hilton Waldorf,
Aldwych, London WC2B 4DD |
About Cellular Biomedicine
GroupCellular Biomedicine Group, Inc. (NASDAQ:CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of twelve
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. CBMG
currently has ongoing CAR-T Phase I clinical trials in China;
CARD-1 for Diffuse Large B-cell Lymphoma (DLBCL) and Non-Hodgkin
Lymphoma (NHL) and CALL-1 for adult Acute Lymphoblastic Leukemia
(ALL), utilizing CBMG’s proprietary and optimized CD19 construct,
as well as an ongoing Phase I trial in China for
AlloJoin™ (CBMG’s “Off-the-Shelf” Allogeneic Human
Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee
Osteoarthritis (KOA). To learn more about CBMG, please visit
www.cellbiomedgroup.com.
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include risks inherent in doing business, trends affecting the
global economy, including the devaluation of the RMB by China in
August 2015 and other risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contact: Sarah Kelly Director of
Corporate Communications, CBMG +1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024